What specific rare adverse events have been reported to CDC's vaccine safety systems for the 2025 flu vaccines and how frequently?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
CDC systems have flagged a small number of rare adverse events after seasonal influenza vaccination in 2025, most notably Guillain–Barré syndrome (GBS) at an estimated excess risk of about one to two additional cases per million doses and sporadic reports of atypical shoulder injuries and other events submitted to VAERS; detailed, authoritative counts for all rare events for the 2025 vaccines are not published in the provided sources [1] [2]. The CDC emphasizes that VAERS is a passive early‑warning system that collects reports but does not by itself establish causality, and surveillance findings must be interpreted against background rates and active‑surveillance studies [2] [3].
1. What rare events have been reported and how often — the headline numbers
The clearest numerical estimate available in the reporting is CDC’s estimate for Guillain–Barré syndrome after seasonal influenza vaccination: the agency states the actual excess risk is very low, on the order of one to two additional GBS cases per million vaccine doses administered [1]. VAERS and CDC publications also document reports of atypical shoulder pain and dysfunction after inactivated influenza vaccines—often described in surveillance literature as SIRVA (shoulder injury related to vaccine administration)—but the provided CDC summary and cited studies describe these as reported events rather than giving a definitive incidence for 2025 specifically [2].
2. What the CDC’s safety systems collect — and their limits
VAERS is a mandatory reporting channel for certain events by providers and manufacturers and a voluntary channel for the public; it functions as an early‑warning system to detect potential safety signals rather than to prove causation or precise incidence [2]. CDC’s Vaccine Safety Datalink and other active‑surveillance networks and published MMWR analyses are used to estimate rates and compare observed events to expected background rates, but those active studies are described in older-season reviews and methodological papers rather than as an itemized 2025 event table in the supplied sources [3] [4].
3. Types of rare events under surveillance beyond GBS
Beyond Guillain–Barré syndrome and SIRVA, the CDC and its advisory documents note that manufacturers and providers are required to report any adverse events of concern to VAERS, including events listed as contraindications, and that pregnant people and infants are specifically monitored with separate surveillance summaries that historically have not revealed unexpected safety signals for newer vaccine platforms [2] [3]. Clinical study safety summaries for newer or high‑dose/adjuvanted formulations list primarily transient local and systemic reactions (pain, redness, headache, myalgia) as common, while more serious events are described in surveillance reports rather than quantified in the materials provided [5] [2].
4. How frequent is “rare” in context — interpreting the numbers
The GBS estimate — roughly one to two excess cases per million doses — places the risk in an extremely low absolute range compared with the large number of doses distributed [1]. CDC and other public health commentators place that small risk in the context of influenza’s harms (hospitalization and death), and rely on active VE and burden studies to weigh benefits versus rare risks, but the provided sources do not include a comprehensive 2025 numerator/denominator table of all VAERS‑reported rare events to compute event‑specific rates beyond the GBS estimate [4] [6].
5. Caveats, alternative views and gaps in the public record
VAERS reports can include coincidental health events temporally associated with vaccination and are subject to reporting biases; establishing whether reports reflect vaccine causation typically requires follow‑up in active systems such as the Vaccine Safety Datalink or formal epidemiologic studies, which the CDC uses but which are not fully enumerated for 2025 in the supplied excerpts [2] [3]. Some reporting and commentary about vaccine ingredients (e.g., thimerosal) and policy changes have attracted political attention and misinformation, and the CDC has noted policy changes and discussed preservative use without tying those to new patterns of rare adverse events in the material provided [7] [8]. The sources supplied do not provide a comprehensive, item‑by‑item list of all rare events reported to CDC systems in 2025 or their precise counts, so definitive frequency tables for every rare outcome cannot be produced from these documents alone [2].